Showing 6361-6370 of 9765 results for "".
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,
- IL-17A Inhibitors Linked with Scalp and Gut Microbiota Improvement in Psoriasis Patientshttps://practicaldermatology.com/news/il-17a-inhibitors-linked-with-scalp-and-gut-microbiota-improvement-in-psoriasis-patients/2484034/Treatment with IL-17A inhibitors may help rebalance disrupted scalp and gut microbiota in patients with moderate-to-severe psoriasis vulgaris, according to a new study. Researchers collected scalp and fecal samples from 15 adu
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat